Trials / Recruiting
RecruitingNCT06387381
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- First Affiliated Hospital of Chongqing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA/FAP positive diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Ga-PSFA | Each subject receives a single intravenous injection of 68Ga-PSFA. |
Timeline
- Start date
- 2024-05-20
- Primary completion
- 2025-04-30
- Completion
- 2026-12-31
- First posted
- 2024-04-29
- Last updated
- 2025-06-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06387381. Inclusion in this directory is not an endorsement.